159 related articles for article (PubMed ID: 21763973)
1. Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.
Appleby L; Morrissey S; Bellmunt J; Rosenberg J
Hematol Oncol Clin North Am; 2011 Aug; 25(4):893-915. PubMed ID: 21763973
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Tang PA; Vickers MM; Heng DY
Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
[TBL] [Abstract][Full Text] [Related]
3. Selected toxicities of targeted therapies: presentation and management.
Kollmannsberger C; Mitchell T
Semin Oncol; 2013 Aug; 40(4):499-510. PubMed ID: 23972714
[TBL] [Abstract][Full Text] [Related]
4. Toxicities of targeted agents in advanced renal cell carcinoma.
Patel P; Srinivas S
Curr Clin Pharmacol; 2011 Aug; 6(3):181-8. PubMed ID: 21827392
[TBL] [Abstract][Full Text] [Related]
5. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
6. Sequential use of targeted agents in the treatment of renal cell carcinoma.
Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted agents for renal cell carcinoma: the next generation.
Cowey CL; Hutson TE
Clin Adv Hematol Oncol; 2010 May; 8(5):357-60, 361-4. PubMed ID: 20551895
[TBL] [Abstract][Full Text] [Related]
8. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
Barthélémy P; Hoch B; Chevreau C; Joly F; Laguerre B; Lokiec F; Duclos B
Crit Rev Oncol Hematol; 2013 Oct; 88(1):42-56. PubMed ID: 23523056
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.
Tonini G; Fratto ME; Imperatori M; Pantano F; Vincenzi B; Santini D
Expert Rev Anticancer Ther; 2011 Jun; 11(6):921-30. PubMed ID: 21707289
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
De Masson A; Fouchard N; Méry-Bossard L; Dauendorffer JN
Dermatology; 2011; 223(1):4-8. PubMed ID: 21846963
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy in metastatic renal cell cancer.
Ravaud A; Gross-Goupil M; Bellmunt J
Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
[TBL] [Abstract][Full Text] [Related]
12. Sequencing therapy in metastatic renal cell cancer.
Escudier B; Gore M
Semin Oncol; 2013 Aug; 40(4):465-71. PubMed ID: 23972710
[TBL] [Abstract][Full Text] [Related]
13. Non-clear cell advanced kidney cancer: is there a gold standard?
Sánchez P; Calvo E; Durán I
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy for renal cell cancer: current perspectives.
van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome?
Eimer C; Gerullis H; Heuck C; Otto T
Anticancer Drugs; 2011 Jan; 22(1):18-23. PubMed ID: 21037468
[TBL] [Abstract][Full Text] [Related]
17. [Renal cell carcinoma: antiangiogenic therapies and management of the complications. A case report].
Fendler JP; Malavaud B; Gimel P; Duclos B; Chevreau C; Pignot G
Prog Urol; 2010 Mar; 20 Suppl 1():S27-32. PubMed ID: 20493440
[TBL] [Abstract][Full Text] [Related]
18. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
Hall PS; Harshman LC; Srinivas S; Witteles RM
JACC Heart Fail; 2013 Feb; 1(1):72-8. PubMed ID: 24621801
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities.
Cohen RB; Oudard S
Invest New Drugs; 2012 Oct; 30(5):2066-79. PubMed ID: 22327313
[TBL] [Abstract][Full Text] [Related]
20. ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.
Roulin D; Demartines N; Dormond O
Biochem Soc Trans; 2011 Apr; 39(2):492-4. PubMed ID: 21428926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
